Results 71 to 80 of about 100,010 (342)

Self-immolative linkers in polymeric delivery systems [PDF]

, 2011
There has been significant interest in the methodologies of controlled release for a diverse range of applications spanning drug delivery, biological and chemical sensors, and diagnostics.
Blencowe, Christopher A, Greco, Francesca, Hayes, Wayne, Russell, Andrew T, Thornthwaite, David W   +4 more
core   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Research progress of antibody coupling technique in targeted drug delivery

Interdisciplinary Medicine
Antibody‐drug conjugates are a cutting‐edge biotechnology recently attracting wide attention in the medical field. Binding antibodies to drug molecules could deliver drugs precisely to the site of the lesion, which shows great potential in the treatment ...
Meng Li, Tiantian Wang, Dan Tan, Mengqi Wang, Changhai Lei, Yuqing Wang, Shi Hu   +6 more
doaj   +1 more source

Intra-Domain Cysteines (IDC), a New Strategy for the Development of Original Antibody Fragment–Drug Conjugates (FDCs)

Pharmaceutics, 2022
Antibody–drug conjugates (ADCs) derived from a full immunoglobulin-G (IgG) are associated with suboptimal solid-tumor penetration and Fc-mediated toxicities. Antibody fragment–drug conjugates (FDCs) could be an alternative.
Louis Jolivet, Imène Ait Mohamed Amar, Catherine Horiot, Fanny Boursin, Cyril Colas, Stéphanie Letast, Caroline Denevault-Sabourin, Emilie Allard-Vannier, Nicolas Joubert, Nicolas Aubrey   +9 more
doaj   +1 more source

The Dawn of the Antibody–Drug Conjugates Era: How T-DM1 Reinvented the Future of Chemotherapy for Solid Tumors [PDF]

, 2022
Paolo Tarantino, Sara M. Tolaney
openalex   +1 more source

Human Vault Nanoparticle Targeted Delivery of Antiretroviral Drugs to Inhibit Human Immunodeficiency Virus Type 1 Infection. [PDF]

, 2019
"Vaults" are ubiquitously expressed endogenous ribonucleoprotein nanoparticles with potential utility for targeted drug delivery. Here, we show that recombinant human vault nanoparticles are readily engulfed by certain key human peripheral blood ...
Anton, Peter A, Deming, Timothy, Elliott, Julie, Fulcher, Jennifer A, Ibarrondo, F Javier, Kickhoefer, Valerie A, Maynard, Heather D, Mrazek, Jan, Rome, Leonard H, Tamshen, Kyle, Wollenberg, Alexander L, Yang, Otto O   +11 more
core  

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

Molecular Oncology, EarlyView.
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son, Lily L. Remsing Rix, Bin Fang, Eric A. Welsh, Nicole V. Bremer, Valentina Foglizzo, Paola Roa, Nickole Sigcha‐Coello, Yi Liao, Eric B. Haura, Alexander Drilon, John M. Koomen, Emiliano Cocco, Uwe Rix   +13 more
wiley   +1 more source

A bispecific antibody–drug conjugate targeting CD7 and CD33 shows anti-tumor activity and improved tumor selectivity in an aggressive subtype of acute myeloid leukemia

mAbs
Acute myeloid leukemia (AML) is a heterogeneous malignancy with poor clinical outcome. Aberrant expression of CD7 in AML patients is linked to shorter overall survival and lack of response to standard of care therapy.
Hollie B. S. Griffiths, Nyle Jones, Mattia Vitale, Nikhil Faulkner, Edward W. Masters, Naomi L. A. Nabi-Aldridge, Meera Mistry, Chloe Patterson, Adrian Blanco-Gomez, Emmanuel Griessinger, Oliver Schon, Tiffany J. Daniels-Thorn   +11 more
doaj   +1 more source

PR062/#686  First-in-human phase 1 study of torl-1–23, a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) in patients with ovarian cancer [PDF]

, 2023
Gottfried E. Konecny, Andrea Wahner Hendrickson, Boris Winterhoff, Cinthiya Chander, Sanela Bilic, Simon Davenport, Adrine Chung, L.L. Miller, Michael F. Press, Stephen P. Letrent, Dennis J. Slamon   +10 more
openalex   +1 more source

Antibody Drug Conjugates: Preclinical Considerations [PDF]

The AAPS Journal, 2015
The development path for antibody drug conjugates (ADCs) is more complex and challenging than for unmodified antibodies. While many of the preclinical considerations for both unmodified and antibody drug conjugates are shared, special considerations must be taken into account when developing an ADC.
openaire   +2 more sources